Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Sheshadri A, Goizueta A, Shannon V, London D, Garcia‐Manero G, Kantarjian H, Ravandi‐Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Zarifa A, Albittar A, Zhong L, Akhmedzhanov F, Arain M, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza T, Godoy M, Shroff G, Kim S, Faiz S, Kontoyiannis D, Khawaja F, Jennings K, Daver N. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 2022, 128: 2736-2745. PMID: 35452134, PMCID: PMC9232977, DOI: 10.1002/cncr.34229.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute myeloid leukemiaImmune checkpoint inhibitor therapyAcute myeloid leukemia patientsICI-related pneumonitisPneumonitis riskMyeloid leukemiaCheckpoint inhibitorsEffect of immune checkpoint inhibitorsFemale sexReduced T-cell functionRisk factorsMultivariate Cox proportional hazards modelICI-containing regimensMultidisciplinary adjudication committeeRate of pneumonitisCheckpoint inhibitor therapyTreating acute myeloid leukemiaIncreased platelet countIncreased mortalityResponse to therapyT cell functionRetrospective cohort studyAttack cancer cellsCox proportional hazards models